LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 104

Search options

  1. Article ; Online: COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?

    Tadic, Marijana / Cuspidi, Cesare / Mancia, Giuseppe / Dell'Oro, Raffaella / Grassi, Guido

    Pharmacological research

    2020  Volume 158, Page(s) 104906

    Abstract: ... Recent data are showing significant prevalence of arterial hypertension and cardiovascular diseases (CVD ... in patients with COVID-19, their influence on the outcome and the effect of treatment of hypertension and CVD ... The evaluation of the treatment of these comorbidities at baseline and during COVID-19 is scarce and the results ...

    Abstract The coronavirus disease (COVID-19) has spread all around the world in a very short period of time. Recent data are showing significant prevalence of arterial hypertension and cardiovascular diseases (CVD) among patients with COVID-19, which raised many questions about higher susceptibility of patients with these comorbidities to the novel coronavirus, as well as the role of hypertension and CVD in progression and the prognosis of COVID-19 patients. There is a very limited amount of data, usually obtained from a small population, regarding the effect of the underlying disease on the outcome in patients with COVID-19. The evaluation of the treatment of these comorbidities at baseline and during COVID-19 is scarce and the results are conflicting. Hypertension and CVD, after the adjustment for other clinical and demographic parameters, primarily age, did not remain independent predictors of the lethal outcome in COVID-19 patients. Some investigations speculated about the association between the renin-angiotensin-aldosterone system (RAAS) and susceptibility to COVID-19, as well as the relationship between RAAS inhibitors and the adverse outcome in these patients. Withdrawing or switching RAAS inhibitors would have uncertain benefits, but it would definitely have many disadvantages such as uncontrolled hypertension, cardiac function deterioration and renal function impairment, which could potentially induce more complications in patients with COVID-19 than the infection of coronavirus itself. The aim of this review article was to summarize the prevalence of hypertension and CVD in patients with COVID-19, their influence on the outcome and the effect of treatment of hypertension and CVD in COVID-19 patients.
    MeSH term(s) Betacoronavirus ; COVID-19 ; Cardiovascular Diseases/drug therapy ; Cardiovascular Diseases/epidemiology ; Comorbidity ; Coronavirus Infections/diagnosis ; Coronavirus Infections/drug therapy ; Coronavirus Infections/epidemiology ; Disease Progression ; Humans ; Hypertension/drug therapy ; Hypertension/epidemiology ; Pandemics ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/epidemiology ; Prognosis ; Renin-Angiotensin System/drug effects ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-05-13
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 1003347-6
    ISSN 1096-1186 ; 0031-6989 ; 1043-6618
    ISSN (online) 1096-1186
    ISSN 0031-6989 ; 1043-6618
    DOI 10.1016/j.phrs.2020.104906
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 721: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?

    Tadic, Marijana / Cuspidi, Cesare / Mancia, Giuseppe / Dell039, / Oro, Raffaella / Grassi, Guido

    Pharmacol Res

    Abstract: ... Recent data are showing significant prevalence of arterial hypertension and cardiovascular diseases (CVD ... in patients with COVID-19, their influence on the outcome and the effect of treatment of hypertension and CVD ... The evaluation of the treatment of these comorbidities at baseline and during COVID-19 is scarce and the results ...

    Abstract The coronavirus disease (COVID-19) has spread all around the world in a very short period of time. Recent data are showing significant prevalence of arterial hypertension and cardiovascular diseases (CVD) among patients with COVID-19, which raised many questions about higher susceptibility of patients with these comorbidities to the novel coronavirus, as well as the role of hypertension and CVD in progression and the prognosis of COVID-19 patients. There is a very limited amount of data, usually obtained from a small population, regarding the effect of the underlying disease on the outcome in patients with COVID-19. The evaluation of the treatment of these comorbidities at baseline and during COVID-19 is scarce and the results are conflicting. Hypertension and CVD, after the adjustment for other clinical and demographic parameters, primarily age, did not remain independent predictors of the lethal outcome in COVID-19 patients. Some investigations speculated about the association between the renin-angiotensin-aldosterone system (RAAS) and susceptibility to COVID-19, as well as the relationship between RAAS inhibitors and the adverse outcome in these patients. Withdrawing or switching RAAS inhibitors would have uncertain benefits, but it would definitely have many disadvantages such as uncontrolled hypertension, cardiac function deterioration and renal function impairment, which could potentially induce more complications in patients with COVID-19 than the infection of coronavirus itself. The aim of this review article was to summarize the prevalence of hypertension and CVD in patients with COVID-19, their influence on the outcome and the effect of treatment of hypertension and CVD in COVID-19 patients.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #244948
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Impact of COVID-19 on patterns of drug utilization: A case study at national hospital.

    Le-Dang, Minh-Anh / Nguyen-Thi, Hai-Yen / Dinh, Luyen Pham / Ngoc, Danh Le / Le, Nguyen Dang Tu / Thu, Hien Pham / Le, Dinh Thanh

    PloS one

    2024  Volume 19, Issue 1, Page(s) e0297187

    Abstract: ... to the cardiovascular system, three subgroups experienced a sudden and significant increase: cardiac therapy, beta-blocking ... to the cardiovascular system, specifically cardiac therapy, beta-blocking agents, and antihypertensives. Intriguingly, there ... Background: The Coronavirus disease of 2019 (COVID-19) pandemic and the corresponding mitigation ...

    Abstract Background: The Coronavirus disease of 2019 (COVID-19) pandemic and the corresponding mitigation measures have had a discernible impact on drug utilization among outpatients. However, limited research exists on the prescription trends in the elderly population during the pandemic period in Viet Nam.
    Objectives: This study aims to analyze the effects of COVID-19 on outpatient drug utilization patterns at a national geriatric hospital in Ho Chi Minh City before and after the early onset of the pandemic.
    Methods: Data was collected from the prescriptions and administration claims, encompassing the period from January 2016 to December 2022. The dataset was divided into two periods: Period 1: January 2016 to December 2020 and Period 2: January 2021 to December 2022. The drug utilization was measured using DDD/1000P (defined daily doses-DDD per 1000 prescriptions) on a monthly basis. The analysis employed interrupted time series using Autoregressive Integrated Moving Average (ARIMA) to detect changes in drug use levels and rates.
    Results: A total of 1,060,507 and 644,944 outpatient prescriptions from Thong Nhat Hospital were included in Period 1 and Period 2, respectively. The median age of the patients were 58 in Period 1 and 67 years old in Period 2. The most common comorbidities were dyslipidemia, hypertension, and diabetes mellitus. In terms of medication utilization, cardiovascular drugs were the most frequently prescribed, followed by drugs active on the digestive and hormonal systems. The study observed significant surges in the number of prescriptions and the average number of drugs per prescription. However, there were no significant changes in the overall consumption of all drugs. Among the drug groups related to the cardiovascular system, three subgroups experienced a sudden and significant increase: cardiac therapy, beta-blocking agents, and antihypertensives, with increasing consumption levels of 1,177.73 [CI 95%: 79.29; 2,276.16], 73.32 [CI 95%: 28.18; 118.46], and 36.70 [CI 95%: 6.74; 66.66] DDD/1000P, respectively. On the other hand, there was a significant monthly decrease of -31.36 [CI 95%: -57.02; -5.70] DDD/1000P in the consumption of anti-inflammatory and antirheumatic products. Interestingly, there was a significant increase of 74.62 [CI 95%: -0.36; 149.60] DDD/1000P in the use of antigout preparations.
    Conclusion: COVID-19 resulted in a sudden, non-significant increase in overall drug consumption levels among outpatients. Notably, our findings highlight significant increases in the utilization of three drug groups related to the cardiovascular system, specifically cardiac therapy, beta-blocking agents, and antihypertensives. Intriguingly, there was a statistically significant increase in the consumption of antigout preparations, despite a decline in the monthly consumption rate of non-steroidal anti-flammatory drugs (NSAIDs). Further studies in the following years are necessary to provide a more comprehensive understanding of the impact of COVID-19 on outpatient drug utilization patterns.
    MeSH term(s) Humans ; Aged ; Infant ; Child, Preschool ; Child ; Adolescent ; Young Adult ; Adult ; Middle Aged ; Antihypertensive Agents/therapeutic use ; COVID-19/epidemiology ; Drug Utilization ; Cardiovascular Agents/therapeutic use ; Diuretics/therapeutic use ; Adrenergic beta-Antagonists/therapeutic use ; Drug Prescriptions
    Chemical Substances Antihypertensive Agents ; Cardiovascular Agents ; Diuretics ; Adrenergic beta-Antagonists
    Language English
    Publishing date 2024-01-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0297187
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: [COVID-19 and stroke].

    Wada, Kuniyasu / Hashimoto, Yoichiro / Nakajima, Makoto / Ueda, Mitsuharu

    Rinsho shinkeigaku = Clinical neurology

    2020  Volume 60, Issue 12, Page(s) 822–839

    Abstract: ... risk factors such as hypertension and diabetes. In patients with COVID-19, venous thromboembolism is more ... Due to the pandemic of corona virus disease 2019 (COVID-19), the stroke medical care system is ... number of young patients, high D-dimer levels, and higher risk in elderly patients with cardiovascular ...

    Abstract Due to the pandemic of corona virus disease 2019 (COVID-19), the stroke medical care system is unavoidably undergoing major changes such as a decrease in the number of stroke patients receiving consultation, delay in consultation, and a decrease in the number of intravenous thrombolysis and mechanical thrombectomy procedures. Stroke incidence in COVID-19 patients is approximately 1.1%. The features of stroke with COVID-19 have been elucidated: higher incidence in ischemic stroke than hemorrhagic stroke, increasing number of young patients, high D-dimer levels, and higher risk in elderly patients with cardiovascular risk factors such as hypertension and diabetes. In patients with COVID-19, venous thromboembolism is more common than arterial thromboembolism, and stroke is more common than acute coronary syndrome. Protected code stroke (PCS) has been proposed which provides safe, effective and prompt treatment under complete infection control.
    MeSH term(s) Acute Coronary Syndrome/complications ; COVID-19/complications ; Diabetes Mellitus ; Fibrin Fibrinogen Degradation Products/analysis ; Humans ; Hypertension ; Pandemics ; Risk Factors ; Stroke/complications ; Stroke/therapy ; Thrombectomy/statistics & numerical data ; Thrombolytic Therapy/statistics & numerical data ; Venous Thromboembolism/complications
    Chemical Substances Fibrin Fibrinogen Degradation Products ; fibrin fragment D
    Language Japanese
    Publishing date 2020-11-20
    Publishing country Japan
    Document type Journal Article ; Review
    ZDB-ID 604200-4
    ISSN 1882-0654 ; 0009-918X
    ISSN (online) 1882-0654
    ISSN 0009-918X
    DOI 10.5692/clinicalneurol.cn-001529
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 1455: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 223: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Pulmonary Hypertension and COVID-19.

    Castiglione, Laura / Droppa, Michal

    Hamostaseologie

    2021  Volume 42, Issue 4, Page(s) 230–238

    Abstract: ... of inhaled vasodilators in patients with COVID-19. Treatment with inhaled nitric oxide and prostacyclin has ... Coronavirus disease 2019 (COVID-19) is a primary respiratory infectious disease, which can result ... in pulmonary and cardiovascular complications. From its first appearance in the city of Wuhan (China ...

    Abstract Coronavirus disease 2019 (COVID-19) is a primary respiratory infectious disease, which can result in pulmonary and cardiovascular complications. From its first appearance in the city of Wuhan (China), the infection spread worldwide, leading to its declaration as a pandemic on March 11, 2020. Clinical research on SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) suggests that the virus may determine changes in the pulmonary hemodynamics through mechanisms of endothelial dysfunction, vascular leak, thrombotic microangiopathy, and venous thromboembolism that are similar to those leading to pulmonary hypertension (PH). Current available studies report echocardiographic signs of PH in approximately 12 to 13% of hospitalized patients with COVID-19. Those with chronic pulmonary obstructive disease, congestive heart failure, pulmonary embolism, and prior PH are at increased risk to develop or worsen PH. Evidence of PH seems to be associated with increased disease severity and poor outcome. Because of the importance of the pulmonary hemodynamics in the pathophysiology of COVID-19, there is growing interest in exploring the potential therapeutical benefits of inhaled vasodilators in patients with COVID-19. Treatment with inhaled nitric oxide and prostacyclin has shown encouraging results through improvement of systemic oxygenation, reduction of systolic pulmonary arterial pressure, and prevention of right ventricular failure; however, data from randomized control trials are still required.
    MeSH term(s) COVID-19/complications ; Epoprostenol/therapeutic use ; Heart Failure ; Humans ; Hypertension, Pulmonary/diagnosis ; Hypertension, Pulmonary/epidemiology ; Hypertension, Pulmonary/etiology ; Pandemics ; SARS-CoV-2
    Chemical Substances Epoprostenol (DCR9Z582X0)
    Language English
    Publishing date 2021-12-21
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 801512-0
    ISSN 2567-5761 ; 0720-9355
    ISSN (online) 2567-5761
    ISSN 0720-9355
    DOI 10.1055/a-1661-0240
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1631: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Monoclonal antibody therapy in COVID-19.

    Conti, P / Pregliasco, F E / Calvisi, V / Caraffa, Al / Gallenga, C E / Kritas, S K / Ronconi, G

    Journal of biological regulators and homeostatic agents

    2021  Volume 35, Issue 2, Page(s) 423–427

    Abstract: ... therapy in COVID-19 are very promising but the results are not yet definitive and more investigations are ... supervision. COVID-19 has accelerated vaccine therapy but also the use of drugs and monoclonal antibodies ... including diabetics, hypertension and obesity, including subjects suffering from cardiovascular diseases ...

    Abstract Acute severe respiratory syndrome coronavirus-2 (SARS-CoV-2) infection causes coronavirus disease-2019 (COVID-19) which is associated with inflammation, thrombosis edema, hemorrhage, intra-alveolar fibrin deposition, and vascular and pulmonary damage. In COVID-19, the coronavirus activates macrophages by inducing the generation of pro-inflammatory cytokines [interleukin (IL)-1, IL-6, IL-18 and TNF] that can damage endothelial cells, activate platelets and neutrophils to produce thromboxane A2 (TxA2), and mediate thrombus generation. In severe cases, all these phenomena can lead to patient death. The binding of SARS-CoV-2 to the Toll Like Receptor (TLR) results in the release of pro-IL-1β that is cleaved by caspase-1, followed by the production of active mature IL-1β which is the most important cytokine in causing fever and inflammation. Its activation in COVID-19 can cause a "cytokine storm" with serious biological and clinical consequences. Blockade of IL-1 with inhibitory and anti-inflammatory cytokines represents a new therapeutic strategy also for COVID-19. Recently, very rare allergic reactions to vaccines have been reported, with phenomena of pulmonary thrombosis. These side effects have raised substantial concern in the population. Highly allergic subjects should therefore be vaccinated under strict medical supervision. COVID-19 has accelerated vaccine therapy but also the use of drugs and monoclonal antibodies (mABs) which have been used in COVID-19 therapy. They are primarily adopted to treat high-risk mild-to-moderate non-hospitalized patients, and it has been noted that the administration of two mABs gave better results. mABs, other than polyclonal plasma antibodies from infected subjects with SARS-CoV-2, are produced in the laboratory and are intended to fight SARS-CoV-2. They bind specifically to the antigenic determinant of the spike protein, inhibiting the pathogenicity of the virus. The most suitable individuals for mAB therapy are people at particular risk, such as the elderly and those with serious chronic diseases including diabetics, hypertension and obesity, including subjects suffering from cardiovascular diseases. These antibodies have a well-predetermined target, they bind mainly to the protein S (formed by the S1A, B, C and D subtypes), located on the viral surface, and to the S2 protein that acts as a fuser between the virus and the cell membrane. Since mABs are derived from a single splenic immune cell, they are identical and form a cell clone which can neutralize SARS-CoV-2 by binding to the epitope of the virus. However, this COVID-19 therapy may cause several side effects such as mild pain, bleeding, bruising of the skin, soreness, swelling, thrombotic-type episodes, arterial hypertension, changes in heart activity, slowed bone marrow activity, impaired renal function, diarrhea, fatigue, nausea, vomiting, allergic reaction, fever, and possible subsequent infection may occur at the site of injection. In conclusion, the studies promoting mAB therapy in COVID-19 are very promising but the results are not yet definitive and more investigations are needed to certify both their good neutralizing effects of SARS-CoV-2, and to eliminate, or at least mitigate, the harmful side effects.
    MeSH term(s) Aged ; Antibodies, Monoclonal ; COVID-19 ; Cytokine Release Syndrome ; Endothelial Cells ; Humans ; SARS-CoV-2
    Chemical Substances Antibodies, Monoclonal
    Language English
    Publishing date 2021-04-27
    Publishing country Italy
    Document type Editorial
    ZDB-ID 639196-5
    ISSN 1724-6083 ; 0393-974X
    ISSN (online) 1724-6083
    ISSN 0393-974X
    DOI 10.23812/Conti_Edit_35_2_1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2270: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: The impact of the COVID-19 pandemic on cardiovascular disease prevention and management.

    Dale, Caroline E / Takhar, Rohan / Carragher, Raymond / Katsoulis, Michail / Torabi, Fatemeh / Duffield, Stephen / Kent, Seamus / Mueller, Tanja / Kurdi, Amanj / Le Anh, Thu Nguyen / McTaggart, Stuart / Abbasizanjani, Hoda / Hollings, Sam / Scourfield, Andrew / Lyons, Ronan A / Griffiths, Rowena / Lyons, Jane / Davies, Gareth / Harris, Daniel /
    Handy, Alex / Mizani, Mehrdad A / Tomlinson, Christopher / Thygesen, Johan H / Ashworth, Mark / Denaxas, Spiros / Banerjee, Amitava / Sterne, Jonathan A C / Brown, Paul / Bullard, Ian / Priedon, Rouven / Mamas, Mamas A / Slee, Ann / Lorgelly, Paula / Pirmohamed, Munir / Khunti, Kamlesh / Morris, Andrew D / Sudlow, Cathie / Akbari, Ashley / Bennie, Marion / Sattar, Naveed / Sofat, Reecha

    Nature medicine

    2023  Volume 29, Issue 1, Page(s) 219–225

    Abstract: How the Coronavirus Disease 2019 (COVID-19) pandemic has affected prevention and management ... we describe monthly counts of prevalent and incident medications dispensed, as well as percentage changes ... impact of the COVID-19 pandemic. ...

    Abstract How the Coronavirus Disease 2019 (COVID-19) pandemic has affected prevention and management of cardiovascular disease (CVD) is not fully understood. In this study, we used medication data as a proxy for CVD management using routinely collected, de-identified, individual-level data comprising 1.32 billion records of community-dispensed CVD medications from England, Scotland and Wales between April 2018 and July 2021. Here we describe monthly counts of prevalent and incident medications dispensed, as well as percentage changes compared to the previous year, for several CVD-related indications, focusing on hypertension, hypercholesterolemia and diabetes. We observed a decline in the dispensing of antihypertensive medications between March 2020 and July 2021, with 491,306 fewer individuals initiating treatment than expected. This decline was predicted to result in 13,662 additional CVD events, including 2,281 cases of myocardial infarction and 3,474 cases of stroke, should individuals remain untreated over their lifecourse. Incident use of lipid-lowering medications decreased by 16,744 patients per month during the first half of 2021 as compared to 2019. By contrast, incident use of medications to treat type 2 diabetes mellitus, other than insulin, increased by approximately 623 patients per month for the same time period. In light of these results, methods to identify and treat individuals who have missed treatment for CVD risk factors and remain undiagnosed are urgently required to avoid large numbers of excess future CVD events, an indirect impact of the COVID-19 pandemic.
    MeSH term(s) Humans ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/prevention & control ; Cardiovascular Diseases/diagnosis ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/epidemiology ; Pandemics/prevention & control ; COVID-19/epidemiology ; Hypertension/complications ; Hypertension/drug therapy ; Hypertension/epidemiology ; Risk Factors
    Language English
    Publishing date 2023-01-19
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-022-02158-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4212: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 39: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: The potential role of ferroptosis in COVID-19-related cardiovascular injury.

    Yang, Lei / Wu, Yunyi / Jin, Weidong / Mo, Nan / Ye, Gaoqi / Su, Zixin / Tang, Lusheng / Wang, Ying / Li, Yanchun / Du, Jing

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    2023  Volume 168, Page(s) 115637

    Abstract: ... in cancer, ischemia/reperfusion injury (I/RI), and other cardiovascular diseases. Altered iron metabolism ... of COVID-19-related cardiovascular injury. SARS-CoV-2 can cause cardiovascular ferroptosis, leading ... to cardiovascular damage. Understanding the mechanism of ferroptosis in COVID-19-related cardiovascular ...

    Abstract COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged as a global health threat in 2019. An important feature of the disease is that multiorgan symptoms of SARS-CoV-2 infection persist after recovery. Evidence indicates that people who recovered from COVID-19, even those under the age of 65 years without cardiovascular risk factors such as smoking, obesity, hypertension, and diabetes, had a significantly increased risk of cardiovascular disease for up to one year after diagnosis. Therefore, it is important to closely monitor individuals who have recovered from COVID-19 for potential cardiovascular damage that may manifest at a later stage. Ferroptosis is an iron-dependent form of non-apoptotic cell death characterized by the production of reactive oxygen species (ROS) and increased lipid peroxide levels. Several studies have demonstrated that ferroptosis plays an important role in cancer, ischemia/reperfusion injury (I/RI), and other cardiovascular diseases. Altered iron metabolism, upregulation of reactive oxygen species, and glutathione peroxidase 4 inactivation are striking features of COVID-19-related cardiovascular injury. SARS-CoV-2 can cause cardiovascular ferroptosis, leading to cardiovascular damage. Understanding the mechanism of ferroptosis in COVID-19-related cardiovascular injuries will contribute to the development of treatment regimens for preventing or reducing COVID-19-related cardiovascular complications. In this article, we go over the pathophysiological underpinnings of SARS-CoV-2-induced acute and chronic cardiovascular injury, the function of ferroptosis, and prospective treatment approaches.
    MeSH term(s) Humans ; Aged ; Ferroptosis/physiology ; Reactive Oxygen Species/metabolism ; COVID-19/complications ; Cardiovascular Diseases/etiology ; SARS-CoV-2/metabolism ; Iron/metabolism ; Reperfusion Injury
    Chemical Substances Reactive Oxygen Species ; Iron (E1UOL152H7)
    Language English
    Publishing date 2023-10-14
    Publishing country France
    Document type Journal Article ; Review
    ZDB-ID 392415-4
    ISSN 1950-6007 ; 0753-3322 ; 0300-0893
    ISSN (online) 1950-6007
    ISSN 0753-3322 ; 0300-0893
    DOI 10.1016/j.biopha.2023.115637
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.198: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Ambulatory blood pressure monitoring in treated patients with hypertension in the COVID-19 pandemic - The study of European society of hypertension (ESH ABPM COVID-19 study).

    Wojciechowska, Wiktoria / Rajzer, Marek / Weber, Thomas / Prejbisz, Aleksander / Dobrowolski, Piotr / Ostrowska, Aleksandra / Bilo, Grzegorz / Mancia, Giuseppe / Kreutz, Reinhold / Januszewicz, Andrzej

    Blood pressure

    2023  Volume 32, Issue 1, Page(s) 2161998

    Abstract: Purpose: The coronavirus disease 2019 (COVID-19) pandemic and the subsequent lockdown profoundly ... for increased blood pressure (BP) and hypertension may also demonstrate significant changes during the pandemic ... masked hypertension) between the two respective ABPM recordings and compare these changes between the two groups ...

    Abstract Purpose: The coronavirus disease 2019 (COVID-19) pandemic and the subsequent lockdown profoundly affected almost all aspects of daily life including health services worldwide. The established risk factors for increased blood pressure (BP) and hypertension may also demonstrate significant changes during the pandemic. This study aims to determine the impact of the COVID-19 pandemic on BP control and BP phenotypes as assessed with 24-hour ambulatory BP monitoring (ABPM).
    Materials and methods: This is a multi-centre, observational, retrospective and comparative study involving Excellence Centres of the European Society of Hypertension across Europe. Along with clinical data and office BP, ABPM recordings will be collected in adult patients with treated arterial hypertension. There will be two groups in the study: Group 1 will consist of participants who have undergone two ABPM recordings - the second one occurring during the COVID-19 pandemic, i.e. after March 2020, and the first one 9-15 months prior to the second. Participants in Group 2 will have two repeated ABPM recordings - both performed before the pandemic within a similar 9-15 month interval between the recordings. Within each group, we will analyse and compare BP variables and phenotypes (including averaged daytime and night-time BP, BP variability, dipper and non-dipper status, white-coat and masked hypertension) between the two respective ABPM recordings and compare these changes between the two groups. The target sample size will amount to least 590 participants in each of the study groups, which means a total of at least 2360 ABPM recordings overall.
    Expected outcomes: As a result, we expect to identify the impact of a COVID-19 pandemic on blood pressure control and the quality of medical care in order to develop the strategy to control cardiovascular risk factors during unpredictable global events.
    MeSH term(s) Humans ; Blood Pressure Monitoring, Ambulatory ; Pandemics ; Retrospective Studies ; COVID-19/epidemiology ; Communicable Disease Control ; Hypertension/drug therapy ; Hypertension/epidemiology ; Blood Pressure/physiology
    Language English
    Publishing date 2023-01-24
    Publishing country England
    Document type Observational Study ; Multicenter Study ; Journal Article
    ZDB-ID 1170048-8
    ISSN 1651-1999 ; 1651-2480 ; 0803-7051 ; 0803-8023
    ISSN (online) 1651-1999 ; 1651-2480
    ISSN 0803-7051 ; 0803-8023
    DOI 10.1080/08037051.2022.2161998
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3843: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease.

    Jeeyavudeen, Mohammad Sadiq / Chaudhari, Rahul / Pappachan, Joseph M / Fouda, Sherouk

    World journal of gastroenterology

    2023  Volume 29, Issue 3, Page(s) 487–502

    Abstract: ... and adaptive immunity alterations in MAFLD patients may influence the severity of COVID-19 ... syndrome, and metabolic-associated fatty liver disease (MAFLD), COVID-19 has gained much attention ... cardiovascular disease, renal disease, malignancy, hypertension, and old age are prone to develop severe disease. There ...

    Abstract People across the world are affected by the "coronavirus disease 2019 (COVID-19)", brought on by the "SARS-CoV type-2 coronavirus". Due to its high incidence in individuals with diabetes, metabolic syndrome, and metabolic-associated fatty liver disease (MAFLD), COVID-19 has gained much attention. The metabolic syndrome's hepatic manifestation, MAFLD, carries a significant risk of type-2-diabetes. The link between the above two conditions has also drawn increasing consideration since MAFLD is intricately linked to the obesity epidemic. Independent of the metabolic syndrome, MAFLD may impact the severity of the viral infections, including COVID-19 or may even be a risk factor. An important question is whether the present COVID-19 pandemic has been fueled by the obesity and MAFLD epidemics. Many liver markers are seen elevated in COVID-19. MAFLD patients with associated comorbid conditions like obesity, cardiovascular disease, renal disease, malignancy, hypertension, and old age are prone to develop severe disease. There is an urgent need for more studies to determine the link between the two conditions and whether it might account for racial differences in the mortality and morbidity rates linked to COVID-19. The role of innate and adaptive immunity alterations in MAFLD patients may influence the severity of COVID-19. This review investigates the implications of COVID-19 on liver injury and disease severity and vice-versa. We also addressed the severity of COVID-19 in patients with prior MAFLD and its potential implications and therapeutic administration in the clinical setting.
    MeSH term(s) Humans ; COVID-19/complications ; Metabolic Syndrome/complications ; Metabolic Syndrome/epidemiology ; Pandemics ; Non-alcoholic Fatty Liver Disease/complications ; Non-alcoholic Fatty Liver Disease/epidemiology ; SARS-CoV-2 ; Diabetes Mellitus, Type 2 ; Obesity/complications ; Obesity/epidemiology
    Language English
    Publishing date 2023-01-04
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2185929-2
    ISSN 2219-2840 ; 1007-9327
    ISSN (online) 2219-2840
    ISSN 1007-9327
    DOI 10.3748/wjg.v29.i3.487
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6039: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top